'Cholangiocarcinoma is a disease with high unmet medical needs that has limited treatment options. Currently, FGFR2 is identified as a driver gene for cholangiocarcinoma and molecular-targeted therapies are being evaluated to treat the disease,' said Dr.
The filing aims to expand the use as a companion diagnostic to identify patients who could benefit from pemigatinib for the treatment of FGFR2 fusion positive locally advanced or metastatic cholangiocarcinoma by detecting FGFR2 fusion genes. Incyte Biosciences Japan submitted an application for pemigatinib for the treatment of FGFR2 fusion positive locally advanced or metastatic cholangiocarcinoma to the MHLW on
As a leading company in the field of oncology, Chugai is committed to realizing advanced personalized oncology care and contributing to patients and healthcare professionals through improving access to comprehensive genomic profiling.
About FoundationOne CDx Cancer Genomic Profile
Developed by
About FGFR
Fibroblast growth factor receptors (FGFRs) play an important role in tumor cell proliferation and survival, migration and angiogenesis (the formation of new blood vessels). Activating mutations, translocations and gene amplifications in FGFRs are closely correlated with the development of various cancers.
Contact:
Tel: +81-3-3273-0881
Email: pr@chugai-pharm.co.jp
(C) 2020 Electronic News Publishing, source